Efficacy and Safety of Granulocytapheresis against severe alcoholic hepatitis

Efficacy and Safety of Granulocytapheresis against severe alcoholic hepatitis - Granulocytapheresis against severe alcoholic hepatitis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019351

Enrollment

Registered

2015-10-14

Start date

2015-10-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe alcoholic hepatitis

Interventions

granulocytapheresis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: the patients who meet the diagnostic criteria of severe alcoholic hepatitis the patients who are able to keep vascular access the patients who obtained their written informed consent

Exclusion criteria

Exclusion criteria: the patients whose granulocyte count are below 2000 the patients who complicated with severe infection, severe heart disease, uncontrolled cancer, and end-stage liver cirrhosis the patients who are pregnant

Design outcomes

Primary

Measure	Time frame
Outcome at 180 days after the initiation of granulocytapheresis	—

Secondary

Measure	Time frame
Changes in clinical parameters including prognostic scores before and after granulocytapheresis Overall survival during observation culmative rate of discharge from Liver Unit after granulocytapheresis Culmative rate of alcoho relapse after granulocytapheresis Safty	—

Countries

Japan

Contacts

Public ContactNobuhiro Nakamoto

School of Medicine, Keio University Division of Gastroenterology & Hepatology, Department of Internal Medicine

nobuhiro@z2.keio.jp03-3353-1211-62384

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026